Ukraine Buys 12,000 Doses of Israeli Drug to Counter Nuclear Threat
World
Ukraine has purchased 12,000 doses of the PLX-R18 drug from Israeli biotechnology company Pluri to combat the effects of ionizing radiation. PLX-R18 is not an ordinary drug — it is produced using stem cells derived from the placentas of women who gave birth via cesarean section. This initiative aims to protect the Ukrainian population from nuclear radiation. The report was published by The Times of Israel.
PLX-R18 is cultivated in special bioreactors and injected into a patient's muscle to help activate the body’s blood cell production system. In the event of a nuclear disaster, such a drug could be the difference between life and death.
According to Israel's Ambassador to Ukraine, Michael Brodsky, the drug aids in restoring platelets as well as red and white blood cells damaged by radiation. These doses, sufficient to treat 6,000 people, will be immediately distributed to hospitals across Ukraine in case of a nuclear emergency.
Hemafund, Ukraine’s umbilical cord blood bank, plans to introduce the drug in the country, conduct clinical trials, and officially register it with the Ministry of Health. The organization claims that the cooperation could bring over $100 million in economic benefit to both parties. But most importantly, it is an investment in human life.
Ukraine views this move not only from a public health perspective, but also as part of its national security strategy.
As Pluri’s Commercial Director Nimrod Bar Svi noted, animal testing showed that the drug increased survival rates from 4% to 74%.
According to Israel's Ambassador to Ukraine, Michael Brodsky, the drug aids in restoring platelets as well as red and white blood cells damaged by radiation. These doses, sufficient to treat 6,000 people, will be immediately distributed to hospitals across Ukraine in case of a nuclear emergency.
Hemafund, Ukraine’s umbilical cord blood bank, plans to introduce the drug in the country, conduct clinical trials, and officially register it with the Ministry of Health. The organization claims that the cooperation could bring over $100 million in economic benefit to both parties. But most importantly, it is an investment in human life.
Ukraine views this move not only from a public health perspective, but also as part of its national security strategy.
As Pluri’s Commercial Director Nimrod Bar Svi noted, animal testing showed that the drug increased survival rates from 4% to 74%.
Powered by Froala Editor